The purpose of this study is to demonstrate that Anecortave Acetate is as effective after
twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible
for initial PDT treatment for wet age-related macular degeneration.
Patients of any race, either gender, aged 50 years and above, diagnosed with subfoveal CNV
due to AMD with best corrected logMAR visual acuity of 20/40 (snellen equivalent) to
20/400 (Snellen equivalent) in the study eye. Clinically relevant concomitant diseases
will be excluded.